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performance status, and adverse effect of afatinib had better PFS. Age, gender, smoking
status, decreased dosage of afatinib would not comprised the efficancy.
Conclusions: Afatinib had significant benefits in progression-free survival in non-
small smallcell lung cancers harboring EGFR-activating mutations. Patients who had
L858R mutation, performance status of ECOG PS 01, and adverse events had better
survival.
Legal entity responsible for the study: This is a study without legal entity responsible
for the governance, coordination and running of the study.
Funding: None
Disclosure: All authors have declared no conflicts of interest.
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Background: Patients with epidermal growth factor receptor (EGFR) mutant advanced
non-small cell lung cancer receiving first-line EGFR-tyrosine kinase inhibitor (TKI)
inevitably developed disease progression after 9-13 months.
Methods: Before 1st January 2017, patients were investigated for resistance mechanisms
upon failure of first-line EGFR-TKI by means of tissue re-biopsy or liquid biopsy to
detect secondary T790M mutation in plasma cell free tumor-DNA (cfDNA) if tissue re-
biopsy could not be performed. After that, liquid biopsy followed by tumor re-biopsy if
cfDNA was negative for T790M mutation or if the patients had rapidly enlarging
tumors.
Results: Of 45 patients who were tested, 31(68.9%) underwent tissue re-biopsy and 14
(31.1%) underwent liquid biopsy as the first investigation to determine the presence of
T790M mutation. For the latter group, 4 (8.9%) subsequently also had tumor re-
biopsy. T790M mutation was detected in 30 (66.7%) of the 45 patients. C-Met amplifi-
cation was tested in 7 T790M mutation-negative patients for possible recruitment into
a clinical trial with 4 showing c-Met amplification. Small cell lung cancer transforma-
tion and ALK rearrangement were detected in 2 (5.7%) and in 1 (2.9%) of the re-biopsy
tissue specimens, respectively. The resistance mechanisms in 8 patients (17.8%) was
unknown. In short, two-third (66.7%) of our patients had T790M mutation upon first-
line EGFR-TKI failure; while another one-third (33.3%) failed first-line EGFR-TKI due
to other resistance mechanisms. The demographic, clinical and treatment characteris-
tics were equally distributed among these 2 groups of patients. (Table)
Conclusions: T790M mutation is the commonest acquired resistance mechanism caus-
ing first-line EGFR-TKI treatment failure. There was no difference in the clinical and
treatment characteristics between patients with and without acquired T790M mutation
as causes of resistance to first-line EGFR-TKI treatment.
Legal entity responsible for the study: Chai Chee Shee, Liam Chong Kin
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Background: The standard care for non-small cell lung cancer (NSCLC) with epider-
mal growth factor receptor (EGFR) gene mutation is EGFR-tyrosine kinase inhibitors
(TKIs). After the tumors acquired resistance to EGFR-TKIs, rebiopsy of the tissue or
liquid biopsy to reveal T790M mutation plays an important role in deciding the next
treatment. Whether rebiopsy contributes to improve the prognosis has not been fully
clarified yet. The aim of this study is to investigate the safety and effectiveness of
rebiopsy in the 1st or 2nd generation EGFR-TKI refractory patients.
Methods: We searched MEDLINE in May 2017 using MeSH and free terms related
non-small cell lung cancer, rebiopsy, and liquid biopsy. We included original articles
and case reports published in English and excluded review articles. We developed ana-
lytic framework (AF) according to AHRQ (Agency for Healthcare Research and
Quality) recommendation. Panel members including oncologist and pulmonologist
experienced over ten years discussed and reached consensus. The AF contains key ques-
tions (KQ) as follows: KQ1 Does rebiopsy in EGFR-TKI refractory patients improve
prognosis? KQ2 What are the rebiopsy samples? KQ3 How are EGFR gene mutations
detected? KQ4 Is the benefit of rebiopsy greater than the harm? KQ5 How often is
T790M mutation detected? KQ6 How is the prognosis when the 3rd generation EGFR-
TKI is administered to T790M positive cases? KQ7 Is the benefit of the 3rd generation
EGFR-TKI greater than the harm? KQ8 How is the prognosis of T790M negative cases?
KQ9 How is the prognosis when rebiopsy is not performed? The primary outcome is
the number of studies which answer KQs.Two authors independently assessed the eligi-
bility based on a full-text review. We resolved disagreements by discussion between the
authors, with another author acting as an arbiter. We summarized the results using
descriptive statistics. Register: CRD42017068630.
Results: We included 59 articles. The numbers of articles which answered to KQ 1-9 are
22, 54, 32, 6, 43, 8, 0, 17 and 0, respectively.
Conclusions: The further investigation will be needed about the real-world safty and
effectiveness of 3rd generation EGFR-TKIs, and the prognosis when rebiopsy could not
be performed after failure of 1st or 2nd generation EGFR-TKIs.
Legal entity responsible for the study: Department of Respiratory Medicine Hyogo
Prefectural Amagasaki General Medical Center
Funding: None
Disclosure: All authors have declared no conflicts of interest.
Table: 430P Demographic, clinical and treatment characteristics of 45 patients with first-line EGFR-TKI treatment failure









Gender, No. (%) Male Female 18 (40.0) 27 (60.0) 13 (43.3) 17 (56.7) 5 (33.3) 10 (66.7) 0.780
Smoking history, No. (%) Never smoker Previous
or current smoker
39 (80.0) 9 (20.0) 22 (73.3) 8 (26.7) 14 (93.3) 1 (6.7) 0.963
EGFR mutation subtype, No. (%) Exon 19 dele-
tion Exon 21 L858R mutation Others Unsure
26 (57.8) 16 (35.6)
2 (4.4) 1 (2.2)
17 (56.7) 12 (40.0)
1 (3.3) 0
9 (60.0) 4 (26.7)
1 (6.7) 1 (6.7)
0.999
Treatment received, No. (%) EGFR-TKI EGFR-TKI
followed by chemotherapy
34 (75.5) 11 (24.5) 22 (73.3) 8 (26.7) 12 (80.0) 5 (20.0) 0.484
Best tumour response, No. (%) Partial response
Stable disease Progression of disease
38 (84.4) 6 (13.3) 1 (2.2) 27 (90.0) 2 (6.7) 1 (3.3) 11 (73.3) 4 (26.7) - 0.419
Progression-free-survival on first-line EGFR-
TKI, months Median
13.0 13.0 11.7 0.538
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